Triple

T22113252
Position Surface form Disambiguated ID Type / Status
Subject Regulation (EC) No 141/2000 on orphan medicinal products E546469 entity
Predicate establishes P986 FINISHED
Object Community register of orphan medicinal products NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Community register of orphan medicinal products | Statement: [Regulation (EC) No 141/2000 on orphan medicinal products, establishes, Community register of orphan medicinal products]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Community register of orphan medicinal products
Context triple: [Regulation (EC) No 141/2000 on orphan medicinal products, establishes, Community register of orphan medicinal products]
  • A. Regulation (EC) No 141/2000 on orphan medicinal products
    Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
  • B. Conditional Marketing Authorization by European Medicines Agency
    Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
  • C. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • D. WHO Collaborating Centre for Drug Statistics Methodology
    The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
  • E. Certificates of Suitability to the monographs of the European Pharmacopoeia
    Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Community register of orphan medicinal products
Target entity description: The Community register of orphan medicinal products is the official European Union list of medicines designated for the diagnosis, prevention, or treatment of rare diseases, maintained under the EU’s orphan drug framework.
  • A. Regulation (EC) No 141/2000 on orphan medicinal products
    Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.
  • B. Conditional Marketing Authorization by European Medicines Agency
    Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
  • C. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • D. WHO Collaborating Centre for Drug Statistics Methodology
    The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
  • E. Certificates of Suitability to the monographs of the European Pharmacopoeia
    Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e38b3848190ac3a4fa97d56e65a completed April 16, 2026, 5:36 p.m.
NER Named-entity recognition batch_69f1294b9d5c8190897b760ca4f3b09a completed April 28, 2026, 9:40 p.m.
Created at: April 16, 2026, 8:31 p.m.